Advancing Dementia Care National Alzheimer’s Buddies’ Fourth Virtual Symposium
Are you curious about how experts in the field are working to advance dementia care?
Former KDKA-TV personality Jon Burnett hopes donating his brain to science will help researchers understand CTE
Former weather anchorman, Jon Burnett, is facing a major health challenge and recently received a diagnosis of suspected chronic traumatic encephalopathy (CTE).
‘We’re still learning’: Diving deeper into Pitt’s National Sports Brain Bank
A team of researchers is quietly working on a new project that could shed more light on the correlation between contact sports and brain injuries.
The grayest of gray matters
What do we really know about Alzheimer’s, and what are the most promising ways to approach the disease? Pitt is building a critical mass of researchers in the search for answers. “Help wanted.” The post-pandemic plea, now commonplace on the doors of restaurants...FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid...One Barrier to Alzheimer’s Diagnoses Could Crumble with Pitt’s Discovery of a Blood Biomarker
Blood-based tests are relatively cheaper and less burdensome to undergo than the alternative imaging tests
National Sports Brain Bank to launch at the University of Pittsburgh
NFL Hall of Famer Jerome Bettis pledges donation to Pitt’s new National Sports Brain Bank
Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease
Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB)
FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Inaugural Ascending Stars Award Winners
Anantha Shekhar,MD, PHD, Senior Vice Chancellor for the Health Sciences at the University of Pittsburgh announced the winners of the inaugural Ascending Stars Award
Dr. Victor Villemagne, MD, Selected for Prestigious 2022 Aging Mind Foundation Award
Dr. Victor Villemagne, MD, a Professor of Psychiatry and Co-Leader of the Alzheimer’s Disease Research Center’s Neuroimaging Core has been awarded the prestigious 2022 Aging Mind Foundation Award.
Can Melatonin Help Prevent Neuron Damage Associated With Dementia?
The Clear Thoughts Foundation (CTF), a Pittsburgh-based nonprofit dedicated to fighting dementia, has awarded $200,000 to co-investigators as part of the CTF Consortium to begin preclinical research on how melatonin might affect dementia-related processes in the brain.
Department of Aging Convenes Alzheimer’s Researchers from Pitt, Penn to Share Prevention and Caregiving Models
The Department of Aging convened a gathering of Alzheimer’s Disease researchers from the University of Pennsylvania’s Perelman School of Medicine and the University of Pittsburgh in a daylong forum to share and discuss their latest work in the areas of prevention, treatment and caregiving.
Frequently asked questions about the newly approved Alzheimer’s drug, Aduhelm™ (aducanumab)
Printable PDF Is this drug a cure for Alzheimer’s disease? No. This medication, marketed under the name Aduhelm™, is not a cure. It does not reverse damage already caused by Alzheimer’s disease, nor does it completely stop the disease. Aducanumab works to slow the...Interested in volunteering for research on Alzheimer’s, related dementias, and cognitive health?
Alzheimer’s Prevention Registry Get information and updates about participating in future Alzheimer’s prevention trials. Alzheimer’s Prevention Registry » Alzheimer’s Prevention Trials (APT) Webstudy Enroll to track memory and thinking skills, and...NIA Launches New Website
NIA is pleased to announce www.Alzheimers.gov, a new website designed to educate and support people whose lives are touched by Alzheimer’s disease and related dementias. The website serves as a federal government portal for dementia information and resources.Live Streaming of Garrett Davis’ play, Forget Me Not
Gdavis Productions & Films in association with the University of Pittsburgh Alzheimer’s Disease Research Center presents the free live streaming of Garrett Davis’ award winning stage play, Forget Me Not.
Care Interventions for People Living With Dementia and Their Caregivers
The aging of the U.S. population and the concurrent rise in the number of adults living with dementia underscore the urgent need for a systematic review of the available evidence for care interventions for PLWD and their formal and informal caregivers. The National Institute on Aging commissioned such a review from the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality.
Caregiving in a time of Coronavirus: A message from your Alzheimer’s Disease Research Center
We are addressing this to all the family members and friends who provide care for persons living with Alzheimer’s disease and similar dementias. The care you provide is always vital to the quality of life and well-being of that person. The Novel Coronavirus (COVID-19)...Congressional Leaders Agree on $350 Million Alzheimer’s and Dementia Research Funding Increase
NIH approves a $350 million Alzheimer’s and dementia funding increase for fiscal year 2020.
Youth Movement Against Alzheimer’s chapter (YMAA) at Pitt started by pre-med student
YMAA was charted in 2015 and is the largest youth-led Alzheimer’s 501 (c)(3) non-profit in the nation.
Seeking individuals with Alzheimer’s disease who experience agitation
The Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD) study is a 12-week trial of escitalopram taking place at the University of Pittsburgh Alzheimer’s Disease Research Center. The S-CitAD Study is looking for volunteers who: Have been diagnosed...Researchers identify common type of dementia similar to Alzheimer’s
The disease, called LATE, seems to develop more slowly than Alzheimer’s and to appear later, when people are in their 80s and 90s.
Local Researchers Focusing on Alzheimer’s Disease Prevention
Alzheimer’s disease impacts nearly 6 million Americans. Researchers at the University of Pittsburgh are working to try and figure out why and whether it can be stopped. They say it may start with a walk around the block.
Dr. Jennifer Lingler and Niki Kapsambelis talk about Alzheimer’s disease on KDKA TV
What do we know about AD and how do we treat it? Dr. Jennifer Lingler and Niki Kapsambelis talk to Ken Rice and Sally Stapleton on KD/PG Sunday edition.
